Analyst Julian Harrison of BTIG reiterated a Buy rating on Ardelyx, retaining the price target of $14.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Julian Harrison has given his Buy rating due to a combination of factors that highlight Ardelyx’s strong financial performance and growth potential. The company’s third-quarter earnings for 2025 exceeded expectations, with Ibsrela and Xphozah both outperforming consensus revenue estimates. Ibsrela, in particular, showed impressive growth, with a significant increase in both quarterly and yearly revenues, driven by a rise in new prescriptions and refills.
Furthermore, the management’s optimistic revenue guidance for Ibsrela and Xphozah suggests continued momentum. The large market size for IBS-C treatments and the unmet needs in this area provide a substantial opportunity for Ardelyx, especially as Ibsrela remains the only non-secratagogue treatment available. Additionally, the company’s strategic developments, including the introduction of a next-generation NHE3 inhibitor and key leadership appointments, reinforce its potential for sustained growth. These factors, combined with a valuation analysis, support the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
ARDX’s price has also changed slightly for the past six months – from $5.505 to $5.010, which is a -8.99% drop .